Urolog. pro Praxi, 2003; 1: 14-18

Prevence a léčba tromboembolické nemoci v urologii

MUDr. Dalibor Musil Ph.D, doc. MUDr. Vladimír Študent Ph.D
Urologická klinika FN a LF UP v Olomouci

Keywords: urology, surgical intervention, hypercoagulable states, thrombembolic disease, anticoagulation therapy, LMWH, perioperative hemorrhage.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Musil D, Študent V. Prevence a léčba tromboembolické nemoci v urologii. Urol. praxi. 2003;4(1):14-18.

Tromboembolická choroba představuje hrozbu, která může zvrátit příznivý výsledek operačního výkonu. Operování v malé pánvi a břišní dutině je spojeno se značným rizikem tromboembolie, zvláště u maligních onemocnění. Práce proto přehledně shrnuje současné poznatky týkající se perioperační prevence tromboembolické nemoci a perioperačního podávání perorální antikoagulační léčby u pacientů dlouhodobě na ni z různých důvodů nastavených. Všímá si také rizika perioperačního krvácení při účinné antikoagulační léčbě. Zahrnuty jsou konkrétní profylaktické postupy, používané na Urologické klinice FN v Olomouci.

PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASE IN UROLOGY

Thromboembolic disease still represents a gross threat, which can cause an adverse outcome of favorable surgical intervention. Surgical procedures in minor pelvis and abdominal cavity are associated with a high risk of thromboembolism, mainly in malignancies. Therefore, the paper gives a clear survey of knowledge concerning perioperative prevention of thromboembolism, perioperative administration of oral anticoagulant therapy in patients on longterm anticoagulation therapy from any reason and pays attention to the risk of perioperative hemorrhage under efficient anticoagulant therapy. The concrete prophylactic procedures used in the Department of Urology of Faculty Hospital in Olomouc are described.

Download citation

References

  1. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet, 340, 1992: 873-876. Go to original source...
  2. Bergquist D, et al. Duration of thromboembolic disease prevention by enoxaparine after operation for tumor. NEJM, 2002; 346: 975-980. Go to original source... Go to PubMed...
  3. Carter CJ. The pathophysiology of venous thrombosis. Prog. Cardiovasc. Dis., 1994; 36: 439-446. Go to original source... Go to PubMed...
  4. Flanc C, Kakkar VV, Clarke MB. The detection of venous thrombosis of the legs using 125-I-labeled fibrinogen. Br. J. Surg., 1968; 55: 742-747. Go to original source... Go to PubMed...
  5. Hull R, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med., 1979; 301: 855-858. Go to original source... Go to PubMed...
  6. Hull RD, et al. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation, 1983; 67: 901-906. Go to original source... Go to PubMed...
  7. Kearon C, Hirsh J. Management of antikoagulation before and after elective surgery. NEJM., 1997; 336: 1506-1511. Go to original source... Go to PubMed...
  8. Kovacs MJ, et al. Outpatients treatment of pulmonary embolism with dalteparin. Thromb. Haemost., 2000; 83: 209. Go to original source... Go to PubMed...
  9. Levine MN, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep-vein thrombosis. Thromb. Haemost., 1995; 74: 606-611. Go to original source... Go to PubMed...
  10. Musil D. Hluboká žilní trombóza - současný pohled na etiopatogenezu a diagnostiku. Int. med. pro praxi, 2001; 3, 8: 347-354.
  11. Zohar A, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J. Urol., 2002; 168: 610-614. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.